A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
Total net revenue of $13.9 millionNet income of $2.0 million, or $0.21 net income per share basicAdjusted EBITDA1 of $(0.6) million, which includes EXXUA launch investments$32.6 million cash balance at September 30, 2025Company remains on track to launch EXXUA™...
DENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
DENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
DENVER, CO / ACCESS Newswire / October 10, 2025 /Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for...
Full year fiscal 2025 net revenue of $66.4 millionFull year fiscal 2025 net loss of $13.6 millionFull year fiscal 2025 adjusted EBITDA1 of $9.2 million$31.0 million cash balance at June 30, 2025Exclusive agreement in June 2025 to commercialize EXXUA™ (gepirone)...
DENVER, CO / ACCESS Newswire / September 16, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for...
DENVER, CO / ACCESS Newswire / June 25, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
Term loan maturity extended by 12 months to June 2029Principal balance on term loan expanded to $13.0 million from $11.1 million currentlyExpanded revolving line of credit facility by $1.5 millionExpanded facilities allow for added working capital flexibility as...